Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis
Julia A. Brown(Cornell University), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), John Koreth(Otsuka (Japan)), Vincent T. Ho(Dana-Farber Cancer Institute), Deborah Liney(Dana-Farber Cancer Institute), Thomas R. Spitzer(Harvard University), Haesook T. Kim(Dana-Farber Cancer Institute), Karen K. Ballen(University of Virginia Health System), Philippe Armand(Harvard University), Joseph H. Antin(Dana-Farber Cancer Institute), Robert J. Soiffer(Dana-Farber Cancer Institute), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Eyal C. Attar(Memorial Sloan Kettering Cancer Center), Kristen E. Stevenson(Dana-Farber Cancer Institute), Carol Reynolds(Harvard University), María Inés Herrera(Dana-Farber Cancer Institute), Sean M. McDonough(Harvard University), Bimalangshu R. Dey(Harvard University), Steve McAfee(Massachusetts General Hospital), Jerome Ritz(Dana-Farber Cancer Institute), Grace Kao(University of California, Irvine), Corey Cutler(Harvard University)
Cited by 97
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k